Genotyping Assay Market by Product & Services (Kits, Instruments,Bioinformatics), Technology (PCR, Sequencing, Microarray), Application (Pharmacogenomics, Animal Genetics), End User (PharmaBiotech Companies, Diagnostic Labs) - Global Forecast to 2029
At a CAGR of 13.8% over the course of the projection period, the genotyping assay market is expected to grow from USD 19.4 billion in 2024 to USD 37.1 billion in 2029. Advances in technology and falling DNA sequencing costs are anticipated to propel this market's growth. Recently, the industry has grown at a slower rate due to the increased prevalence of hereditary illnesses. Additionally, the field of customized medicine and medication development has made genotyping a major component.
Opportunities in the market are anticipated to arise from the need for genome analysis in plants and animal livestock, an increasing emphasis on national sequencing programs aimed at establishing genetic connections with disease, and the expanding fields of applications for genotyping. On the other hand, market expansion may be somewhat hampered by the high cost of equipment.
“Reagents & Kits segment accounted for the highest CAGR”
By product & service, the market is primarily segmented into reagents and kits, instruments, GENOTYPING ASSAY services, and bioinformatics. The reagents & kits segment accounted for the largest share of the Genotyping assay in 2023. The availability of a broad variety of reagents, the rising demand for reagents due to the rising volume of GENOTYPING ASSAY tests conducted worldwide, and the comparatively lower initial outlay needed to implement reagents and kits for GENOTYPING Assay in pharmacies and diagnostic facilities are all responsible for this segment's size.
“The polymerase chain reaction (PCR) segment accounted for the market share in the genotyping assay market, by technology, during the forecast period”
By technology, the market is primarily segmented into polymerase chain reaction (PCR), microarrays, capillary electrophoresis, sequencing, matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF), and other technologies (in situ hybridization and allele-specific oligonucleotides). The PCR segment accounted for the largest share of the GENOTYPING ASSAY technology market in 2023. The main factors propelling the growth of the PCR market are the introduction of new technologies like reverse transcriptase PCR, nested PCR, hot-start PCR, allele-specific PCR, and multiplex PCR; technological developments in PCR instruments and reagents; and the growing use of PCR technologies in the domains of genetics, prenatal testing, forensics, and personalized medicine.
“Pharmacogenomics segment accounted for the highest share”
By application, the market is primarily segmented into pharmacogenomics, diagnostics & personalized medicine, agricultural biotechnology, animal genetics, and other applications. The pharmacogenomics segment accounted for the largest share of the GENOTYPING ASSAY applications market in 2023. The primary drivers of growth in this market are the growing need for pharmacogenomics to investigate adverse drug reactions (ADRs) in clinical trials and the requirement to lower the total cost of medication development for pharmaceutical companies. The growing need for customized medication, the rise in hereditary and life-threatening illnesses, and ongoing research into effective and alternative drug delivery strategies are all anticipated to fuel the growth of the pharmacogenomics genotyping test.
“Biopharmaceutical & pharmaceutical companies segment accounted for the highest share”
By end user, the market is primarily segmented into biopharmaceutical & pharmaceutical companies, diagnostic laboratories, academic & research institutes, and other end users. The biopharmaceutical & pharmaceutical companies segment accounted for the largest share of the GENOTYPING ASSAY end-user market in 2023. The growing need for pharmacogenomics in the medication development process, the introduction of new products, and FDA recommendations to incorporate pharmacogenomics studies and GENOTYPING ASSAY in the drug discovery process are all responsible for this segment's size. Furthermore, the expansion of this market sector within GENOTYPING ASSAY is further facilitated by a rise in partnerships and funding for pharmacogenomics research.
“Asia Pacific: The fastest-growing region in cancer biomarkers market”
The global cancer biomarkers market is segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa and GCC Countries. The Asia Pacific region is projected to register the highest CAGR during the forecast period, primarily due to the increasing financial support from public as well as private agencies, increasing number of NGS-based research projects, increasing awareness about precision medicine, and high incidence of chronic diseases.
Breakdown of supply-side primary interviews, by company type, designation, and region:
This research report categorizes the genotyping assay market by product & services, technology, application, end-user, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the optometry equipment market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the genotyping assay market. Competitive analysis of upcoming startups in the optometry equipment market ecosystem is covered in this report.
Reasons to buy this report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall genotyping assay market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
Opportunities in the market are anticipated to arise from the need for genome analysis in plants and animal livestock, an increasing emphasis on national sequencing programs aimed at establishing genetic connections with disease, and the expanding fields of applications for genotyping. On the other hand, market expansion may be somewhat hampered by the high cost of equipment.
“Reagents & Kits segment accounted for the highest CAGR”
By product & service, the market is primarily segmented into reagents and kits, instruments, GENOTYPING ASSAY services, and bioinformatics. The reagents & kits segment accounted for the largest share of the Genotyping assay in 2023. The availability of a broad variety of reagents, the rising demand for reagents due to the rising volume of GENOTYPING ASSAY tests conducted worldwide, and the comparatively lower initial outlay needed to implement reagents and kits for GENOTYPING Assay in pharmacies and diagnostic facilities are all responsible for this segment's size.
“The polymerase chain reaction (PCR) segment accounted for the market share in the genotyping assay market, by technology, during the forecast period”
By technology, the market is primarily segmented into polymerase chain reaction (PCR), microarrays, capillary electrophoresis, sequencing, matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF), and other technologies (in situ hybridization and allele-specific oligonucleotides). The PCR segment accounted for the largest share of the GENOTYPING ASSAY technology market in 2023. The main factors propelling the growth of the PCR market are the introduction of new technologies like reverse transcriptase PCR, nested PCR, hot-start PCR, allele-specific PCR, and multiplex PCR; technological developments in PCR instruments and reagents; and the growing use of PCR technologies in the domains of genetics, prenatal testing, forensics, and personalized medicine.
“Pharmacogenomics segment accounted for the highest share”
By application, the market is primarily segmented into pharmacogenomics, diagnostics & personalized medicine, agricultural biotechnology, animal genetics, and other applications. The pharmacogenomics segment accounted for the largest share of the GENOTYPING ASSAY applications market in 2023. The primary drivers of growth in this market are the growing need for pharmacogenomics to investigate adverse drug reactions (ADRs) in clinical trials and the requirement to lower the total cost of medication development for pharmaceutical companies. The growing need for customized medication, the rise in hereditary and life-threatening illnesses, and ongoing research into effective and alternative drug delivery strategies are all anticipated to fuel the growth of the pharmacogenomics genotyping test.
“Biopharmaceutical & pharmaceutical companies segment accounted for the highest share”
By end user, the market is primarily segmented into biopharmaceutical & pharmaceutical companies, diagnostic laboratories, academic & research institutes, and other end users. The biopharmaceutical & pharmaceutical companies segment accounted for the largest share of the GENOTYPING ASSAY end-user market in 2023. The growing need for pharmacogenomics in the medication development process, the introduction of new products, and FDA recommendations to incorporate pharmacogenomics studies and GENOTYPING ASSAY in the drug discovery process are all responsible for this segment's size. Furthermore, the expansion of this market sector within GENOTYPING ASSAY is further facilitated by a rise in partnerships and funding for pharmacogenomics research.
“Asia Pacific: The fastest-growing region in cancer biomarkers market”
The global cancer biomarkers market is segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa and GCC Countries. The Asia Pacific region is projected to register the highest CAGR during the forecast period, primarily due to the increasing financial support from public as well as private agencies, increasing number of NGS-based research projects, increasing awareness about precision medicine, and high incidence of chronic diseases.
Breakdown of supply-side primary interviews, by company type, designation, and region:
- By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
- By Designation: C-level (27%), Director-level (18%), and Others (55%)
- By Region: North America (51%), Europe (21%), Asia- Pacific (18%), Latin America (6%), and Middle East & Africa(4%)
- Thermo Fisher Scientific Inc. (US),
- Illumina, Inc. (US),
- Danaher Corporation (US),
- QIAGEN (Netherlands),
- Eurofins Scientific (Luxembourg),
- F. Hoffmann-La Roche Ltd. (Switzerland),
- Bio-Rad Laboratories, Inc. (US),
- Merck KGAA (Germany),
- Agilent Technologies (US),
- Revvity Inc. (US),
- Standard Bio Tools (US),
- PacBio (US),
- GENEWIZ Inc. (US),
- Luminex Corporation (Diasorin Company) (US),
- Oxford Nanopore Technologies Plc (UK),
- GenScript (US),
- Takara Bio Inc. (Japan),
- New England Biolabs (US),
- Promega Corporation (US),
- Tecan Trading AG (Switzerland),
- Genotypic Technology Pvt. Ltd. (India),
- BGI GROUP (China),
- Novogene Co., Ltd. (China),
- Paragon Genomics, Inc. (US),
- NeoGenomics Laboratories (US).
This research report categorizes the genotyping assay market by product & services, technology, application, end-user, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the optometry equipment market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the genotyping assay market. Competitive analysis of upcoming startups in the optometry equipment market ecosystem is covered in this report.
Reasons to buy this report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall genotyping assay market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers (Technological advancements and reduced prices of DNA sequencing, Growing importance and use of genotyping in drug discovery and development), restraints (High manufacturing, installation, and maintenance costs of genotyping instruments), opportunities (Increasing application areas in genomics and genotyping analysis for animal genetics and agricultural biotechnology), and challenges (lack of adequate data management in genomics research) influencing the growth of the genotyping assay market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the genotyping assay market
- Market Development: Comprehensive information about lucrative markets – the report analyses the genotyping assay market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the genotyping assay market
- Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Danaher Corporation (US), Eurofins Scientific (Luxembourg), and QIAGEN (Netherlands). among others in genotyping assay market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
TABLE 1 GENOTYPING ASSAY MARKET: INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 SEGMENTS COVERED
FIGURE 1 GENOTYPING ASSAY MARKET: SEGMENTS COVERED
1.3.2 REGIONS COVERED
FIGURE 2 GENOTYPING ASSAY MARKET: REGIONS COVERED
1.3.3 YEARS CONSIDERED
FIGURE 3 GENOTYPING ASSAY MARKET: YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
1.5.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 4 GENOTYPING ASSAY MARKET: RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key secondary sources
2.1.1.2 Key data from secondary sources
FIGURE 5 KEY DATA FROM SECONDARY SOURCES
2.1.1.3 Objectives of secondary research
2.1.2 PRIMARY DATA
2.1.2.1 Key primary sources: Demand and supply sides
FIGURE 6 KEY PRIMARY SOURCES: DEMAND AND SUPPLY SIDES
2.1.2.2 Objectives of primary research
2.1.2.3 Key data from primary sources
TABLE 2 GENOTYPING ASSAY MARKET: KEY DATA FROM PRIMARY SOURCES
2.1.2.4 Insights from primary experts
FIGURE 7 GENOTYPING ASSAY MARKET: KEY INSIGHTS FROM PRIMARY EXPERTS
2.1.2.5 Breakdown of primaries
FIGURE 8 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
FIGURE 9 BREAKDOWN OF PRIMARIES: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Company revenue estimation approach
FIGURE 10 COMPANY REVENUE ESTIMATION APPROACH
2.2.1.2 Company presentations and primary interviews
2.2.1.3 Growth forecasts
2.2.1.4 CAGR projections
FIGURE 11 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.2.2 TOP-DOWN APPROACH
FIGURE 12 GENOTYPING ASSAY MARKET: TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 13 GENOTYPING ASSAY MARKET: DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 STUDY ASSUMPTIONS
2.6 GROWTH RATE ASSUMPTIONS
2.7 RISK ASSESSMENT
TABLE 3 GENOTYPING ASSAY MARKET: RISK ASSESSMENT
2.8 RESEARCH LIMITATIONS
2.9 IMPACT OF ECONOMIC RECESSION ON GENOTYPING ASSAY MARKET
3 EXECUTIVE SUMMARY
FIGURE 14 GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION)
FIGURE 15 GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 16 GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 17 GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
FIGURE 18 GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 19 GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 20 GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 21 GENOTYPING ASSAY MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
FIGURE 22 GENOTYPING ASSAY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 23 GENOTYPING ASSAY MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)
4 PREMIUM INSIGHTS
4.1 GENOTYPING ASSAY MARKET OVERVIEW
FIGURE 24 TECHNOLOGICAL ADVANCEMENTS AND REDUCED PRICES OF DNA SEQUENCING TO DRIVE MARKET
4.2 GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029
FIGURE 25 REAGENTS & KITS TO COMMAND LARGEST MARKET SHARE DURING FORECAST PERIOD
4.3 GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2024 VS. 2029
FIGURE 26 POLYMERASE CHAIN REACTION TO POSSESS LARGEST MARKET SHARE BETWEEN 2024 AND 2029
4.4 GENOTYPING ASSAY MARKET, BY APPLICATION, 2024 VS. 2029
FIGURE 27 PHARMACOGENOMICS TO ACCOUNT FOR LARGEST MARKET SHARE DURING STUDY PERIOD
4.5 GENOTYPING ASSAY MARKET, BY END USER, 2024 VS. 2029
FIGURE 28 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO COMMAND LARGEST MARKET SHARE FROM 2024 TO 2029
4.6 GENOTYPING ASSAY MARKET: REGIONAL GROWTH OPPORTUNITIES (2024–2029)
FIGURE 29 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 30 GENOTYPING ASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Technological advancements and reduced prices of DNA sequencing
FIGURE 31 COST OF HUMAN WHOLE-GENOME SEQUENCING, 2002–2022
5.2.1.2 Increasing incidence of genetic diseases and rising use of personalized medicines
5.2.1.3 Growing importance and use of genotyping in drug discovery and development
5.2.1.4 Increasing demand for bioinformatics solutions in data analysis
5.2.2 RESTRAINTS
5.2.2.1 High manufacturing, installation, and maintenance costs of genotyping instruments
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing use of genomics in animal genetics and agricultural biotechnology
5.2.4 CHALLENGES
5.2.4.1 Lack of adequate data management in genomics research
5.2.4.2 Dearth of trained healthcare personnel for genomic sequencing data analysis
5.3 PRICING ANALYSIS
5.3.1 PRICING ANALYSIS FOR GENOTYPING ASSAY PRODUCTS, 2021–2023
TABLE 4 PRICING ANALYSIS TREND FOR GENOTYPING ASSAY PRODUCTS, 2021–2023
5.3.2 AVERAGE SELLING PRICE OF GENOTYPING ASSAY PRODUCTS, BY REGION, 2021–2023
TABLE 5 AVERAGE SELLING PRICE OF GENOTYPING ASSAY PRODUCTS, BY REGION, 2021–2023
5.4 PATENT ANALYSIS
FIGURE 32 PATENT APPLICATIONS FOR GENOTYPING ASSAY (NEXT-GENERATION SEQUENCING) MARKET, JANUARY 2012–MARCH 2023
TABLE 6 INDICATIVE LIST OF PATENTS IN GENOTYPING ASSAY (NEXT-GENERATION SEQUENCING) MARKET
5.5 VALUE CHAIN ANALYSIS
FIGURE 33 GENOTYPING ASSAY MARKET: VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.6.1 PROMINENT COMPANIES
5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES
5.6.3 END USERS
FIGURE 34 GENOTYPING ASSAY MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
FIGURE 35 GENOTYPING ASSAY MARKET: ECOSYSTEM MAP
5.7.1 ROLE IN ECOSYSTEM
TABLE 7 GENOTYPING ASSAY MARKET: ROLE IN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
FIGURE 36 GENOTYPING ASSAY MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 8 GENOTYPING ASSAY MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF SUPPLIERS
5.8.4 BARGAINING POWER OF BUYERS
5.8.5 INTENSITY OF COMPETITIVE RIVALRY
5.9 KEY STAKEHOLDERS AND BUYING CRITERIA
5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 37 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
TABLE 9 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
5.9.2 KEY BUYING CRITERIA
FIGURE 38 KEY BUYING CRITERIA FOR GENOTYPING ASSAYS
TABLE 10 KEY BUYING CRITERIA FOR GENOTYPING ASSAYS
5.10 REGULATORY ANALYSIS
5.10.1 REGULATORY LANDSCAPE
5.10.1.1 North America
5.10.1.1.1 US
TABLE 11 US FDA: MEDICAL DEVICE CLASSIFICATION
TABLE 12 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
5.10.1.1.2 Canada
5.10.1.2 Europe
5.10.1.3 Asia Pacific
5.10.1.3.1 China
TABLE 13 CHINA: CLASSIFICATION OF MEDICAL DEVICES
5.10.1.3.2 Japan
5.10.1.3.3 India
5.10.1.4 Latin America
5.10.1.5 Middle East
5.11 TRADE ANALYSIS
5.11.1 IMPORT DATA FOR PCR ANALYZERS (HS CODE 3822)
TABLE 14 IMPORT DATA FOR PCR ANALYZERS (HS CODE 3822), BY COUNTRY, 2017–2021 (USD)
5.11.2 EXPORT DATA FOR PCR ANALYZERS (HS CODE 3822)
TABLE 15 EXPORT DATA FOR PCR ANALYZERS (HS CODE 3822), BY COUNTRY, 2017–2021 (USD)
5.12 TECHNOLOGY ANALYSIS
5.12.1 KEY TECHNOLOGIES
5.12.1.1 Polymerase chain reaction
5.12.1.2 Next-generation sequencing
5.12.2 COMPLEMENTARY TECHNOLOGIES
5.12.2.1 CRISPR-based perturbational
5.12.3 ADJACENT TECHNOLOGIES
5.12.3.1 Single-cell RNA sequencing
5.13 KEY CONFERENCES AND EVENTS, 2024–2025
TABLE 16 GENOTYPING ASSAY MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS, JANUARY 2024–DECEMBER 2025
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 39 REVENUE SHIFT IN GENOTYPING ASSAY MARKET
5.15 CASE STUDY ANALYSIS
5.15.1 DIGITAL PCR FOR GENOTYPE QUANTIFICATION IN PASTA PRODUCTION CHAIN
5.16 INVESTMENT & FUNDING SCENARIO
6 GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
TABLE 17 GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
6.2 REAGENTS & KITS
6.2.1 INCREASING VOLUME OF GENOTYPING TESTS TO DRIVE MARKET
TABLE 18 GENOTYPING ASSAY REAGENTS & KITS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 19 NORTH AMERICA: GENOTYPING ASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 20 EUROPE: GENOTYPING ASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 21 ASIA PACIFIC: GENOTYPING ASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 22 LATIN AMERICA: GENOTYPING ASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.3 GENOTYPING SERVICES
6.3.1 RISING DEMAND FOR SEQUENCING FROM HOSPITALS AND PHARMACEUTICAL COMPANIES TO PROPEL MARKET GROWTH
TABLE 23 GENOTYPING ASSAY SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 24 NORTH AMERICA: GENOTYPING ASSAY SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 25 EUROPE: GENOTYPING ASSAY SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 26 ASIA PACIFIC: GENOTYPING ASSAY SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 27 LATIN AMERICA: GENOTYPING ASSAY SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.4 INSTRUMENTS
TABLE 28 GENOTYPING ASSAY INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 29 NORTH AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 30 EUROPE: GENOTYPING ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 31 ASIA PACIFIC: GENOTYPING ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 32 LATIN AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 33 GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
6.4.1 SEQUENCERS & AMPLIFIERS
6.4.1.1 Decreasing cost of DNA sequencing procedures to aid market growth
TABLE 34 GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 35 NORTH AMERICA: GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 36 EUROPE: GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 37 ASIA PACIFIC: GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 38 LATIN AMERICA: GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.4.2 ANALYZERS
6.4.2.1 Technological advancements in high-throughput analyzers to support market growth
TABLE 39 GENOTYPING ASSAY ANALYZERS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 40 NORTH AMERICA: GENOTYPING ASSAY ANALYZERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 41 EUROPE: GENOTYPING ASSAY ANALYZERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 42 ASIA PACIFIC: GENOTYPING ASSAY ANALYZERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 43 LATIN AMERICA: GENOTYPING ASSAY ANALYZERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.5 BIOINFORMATICS
TABLE 44 GENOTYPING ASSAY BIOINFORMATICS MARKET, BY REGION, 2022–2029, (USD MILLION)
TABLE 45 NORTH AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 46 EUROPE: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 47 ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 48 LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 49 GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
6.5.1 SOFTWARE
6.5.1.1 High volume of sequencing and microarray tests to augment segment growth
TABLE 50 GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 51 NORTH AMERICA: GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 52 EUROPE: GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 53 ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 54 LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.5.2 SERVICES
6.5.2.1 Increasing public-private funding to support segment growth
TABLE 55 GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 56 NORTH AMERICA: GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 57 EUROPE: GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 58 ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 59 LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7 GENOTYPING ASSAY MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 60 GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
7.2 POLYMERASE CHAIN REACTION
TABLE 61 COMPARATIVE STUDY: REAL-TIME POLYMERASE CHAIN REACTION VS. DIGITAL POLYMERASE CHAIN REACTION
TABLE 62 GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 63 GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2022–2029 (USD MILLION)
TABLE 64 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 65 EUROPE: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 66 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 67 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
7.2.1 REAL-TIME POLYMERASE CHAIN REACTION
7.2.1.1 Continuous automation of laboratory techniques to propel market growth
TABLE 68 KEY REAL-TIME POLYMERASE CHAIN REACTION PRODUCTS
TABLE 69 REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 70 NORTH AMERICA: REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 71 EUROPE: REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 72 ASIA PACIFIC: REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 73 LATIN AMERICA: REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7.2.2 DIGITAL POLYMERASE CHAIN REACTION
7.2.2.1 High cost of instruments and lack of knowledge among end users to limit market growth
TABLE 74 KEY DIGITAL POLYMERASE CHAIN REACTION PRODUCTS
TABLE 75 DIGITAL POLYMERASE CHAIN REACTION MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 76 NORTH AMERICA: DIGITAL POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 77 EUROPE: DIGITAL POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 78 ASIA PACIFIC: DIGITAL POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 79 LATIN AMERICA: DIGITAL POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7.3 MICROARRAYS
7.3.1 HIGH DEMAND FOR PERSONALIZED MEDICINES TO DRIVE MARKET
TABLE 80 KEY MICROARRAYS
TABLE 81 GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY REGION, 2022–2029 (USD MILLION)
TABLE 82 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 83 EUROPE: GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 84 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 85 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY COUNTRY, 2022–2029 (USD MILLION)
7.4 SEQUENCING
TABLE 86 GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 87 GENOTYPING ASSAY MARKET FOR SEQUENCING, BY REGION, 2022–2029 (USD MILLION)
TABLE 88 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 89 EUROPE: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 90 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 91 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
7.4.1 NEXT-GENERATION SEQUENCING
7.4.1.1 Higher speed and better accuracy to fuel segment growth
TABLE 92 KEY NEXT-GENERATION SEQUENCING PRODUCTS
TABLE 93 NEXT-GENERATION SEQUENCING MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 94 NORTH AMERICA: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 95 EUROPE: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 96 ASIA PACIFIC: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 97 LATIN AMERICA: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7.4.2 PYROSEQUENCING
7.4.2.1 Growing need for genotyping difficult assays with accurate results to augment growth
TABLE 98 KEY PYROSEQUENCING PRODUCTS
TABLE 99 PYROSEQUENCING MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 100 NORTH AMERICA: PYROSEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 101 EUROPE: PYROSEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 102 ASIA PACIFIC: PYROSEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 103 LATIN AMERICA: PYROSEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7.4.3 SANGER SEQUENCING
7.4.3.1 Increasing use in small-scale experiments to boost segment growth
TABLE 104 KEY SANGER SEQUENCING PRODUCTS
TABLE 105 SANGER SEQUENCING MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 106 NORTH AMERICA: SANGER SEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 107 EUROPE: SANGER SEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 108 ASIA PACIFIC: SANGER SEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 109 LATIN AMERICA: SANGER SEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7.5 CAPILLARY ELECTROPHORESIS
TABLE 110 GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 111 GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY REGION, 2022–2029 (USD MILLION)
TABLE 112 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 113 EUROPE: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 114 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 115 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2022–2029 (USD MILLION)
7.5.1 AMPLIFIED FRAGMENT LENGTH POLYMORPHISM
7.5.1.1 Increasing use in determining genetic differences to drive segment
TABLE 116 AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 117 NORTH AMERICA: AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 118 EUROPE: AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 119 ASIA PACIFIC: AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 120 LATIN AMERICA: AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7.5.2 RESTRICTION FRAGMENT LENGTH POLYMORPHISM
7.5.2.1 Rising demand in forensics and agricultural institutions to support market growth
TABLE 121 KEY RESTRICTION FRAGMENT LENGTH POLYMORPHISM PRODUCTS
TABLE 122 RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 123 NORTH AMERICA: RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 124 EUROPE: RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 125 ASIA PACIFIC: RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 126 LATIN AMERICA: RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7.5.3 SINGLE-STRAND CONFORMATION POLYMORPHISM
7.5.3.1 Increasing applications in virology to boost segment growth
TABLE 127 KEY SINGLE-STRAND CONFORMATION POLYMORPHISM PRODUCTS
TABLE 128 SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 129 NORTH AMERICA: SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 130 EUROPE: SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 131 ASIA PACIFIC: SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 132 LATIN AMERICA: SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7.6 MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY
7.6.1 INCREASING APPLICATIONS IN CLINICAL DIAGNOSTICS AND PHARMACOGENOMICS TO AID MARKET GROWTH
TABLE 133 KEY MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT PRODUCTS
TABLE 134 GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY, BY REGION, 2022–2029 (USD MILLION)
TABLE 135 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 136 EUROPE: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 137 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 138 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
7.7 OTHER TECHNOLOGIES
TABLE 139 OTHER GENOTYPING TECHNOLOGIES
TABLE 140 GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 141 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 142 EUROPE: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 143 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 144 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
8 GENOTYPING ASSAY MARKET, BY APPLICATION
8.1 INTRODUCTION
TABLE 145 GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
8.2 PHARMACOGENOMICS
8.2.1 GROWING DEMAND FOR STUDYING ADVERSE DRUG REACTIONS IN CLINICAL TRIALS TO DRIVE MARKET
TABLE 146 GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY REGION, 2022–2029 (USD MILLION)
TABLE 147 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 148 EUROPE: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 149 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 150 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY, 2022–2029 (USD MILLION)
8.3 DIAGNOSTICS & PERSONALIZED MEDICINES
8.3.1 INCREASING FOCUS ON DEVELOPING DIAGNOSTICS TESTS THROUGH RAPID GENOTYPING TO AID MARKET GROWTH
TABLE 151 GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINES, BY REGION, 2022–2029 (USD MILLION)
TABLE 152 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 153 EUROPE: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 154 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 155 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINES, BY COUNTRY, 2022–2029 (USD MILLION)
8.4 ANIMAL GENETICS
8.4.1 NEED TO INCREASE LIVESTOCK POPULATION TO PROPEL MARKET GROWTH
TABLE 156 GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY REGION, 2022–2029 (USD MILLION)
TABLE 157 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 158 EUROPE: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 159 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 160 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY COUNTRY, 2022–2029 (USD MILLION)
8.5 AGRICULTURAL BIOTECHNOLOGY
8.5.1 INCREASING USE OF PLANT GENOTYPING IN RESEARCH LABORATORIES AND GREENHOUSES TO FUEL MARKET GROWTH
TABLE 161 GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY REGION, 2022–2029 (USD MILLION)
TABLE 162 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 163 EUROPE: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 164 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 165 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
8.6 OTHER APPLICATIONS
TABLE 166 GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 167 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 168 EUROPE: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 169 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 170 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
9 GENOTYPING ASSAY MARKET, BY END USER
9.1 INTRODUCTION
TABLE 171 GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
9.2.1 RISING DEMAND FOR PHARMACOGENOMICS IN DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET
TABLE 172 GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 173 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029(USD MILLION)
TABLE 174 EUROPE: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029(USD MILLION)
TABLE 175 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 176 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
9.3 DIAGNOSTIC LABORATORIES
9.3.1 GROWING PREFERENCE FOR PERSONALIZED MEDICINES TO AUGMENT MARKET GROWTH
TABLE 177 GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 178 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029(USD MILLION)
TABLE 179 EUROPE: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 180 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 181 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
9.4 ACADEMIC & RESEARCH INSTITUTES
9.4.1 INCREASING INDUSTRY-ACADEMIA COLLABORATIONS FOR DRUG DEVELOPMENT TO SUPPORT MARKET GROWTH
TABLE 182 GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION)
TABLE 183 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 184 EUROPE: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 185 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 186 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
9.5 OTHER END USERS
TABLE 187 GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
TABLE 188 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 189 EUROPE: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 190 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 191 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
10 GENOTYPING ASSAY MARKET, BY REGION
10.1 INTRODUCTION
TABLE 192 GENOTYPING ASSAY MARKET, BY REGION, 2022–2029 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 40 NORTH AMERICA: GENOTYPING ASSAY MARKET SNAPSHOT
TABLE 193 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 194 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 195 NORTH AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 196 NORTH AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 197 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 198 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 199 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 200 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 201 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 202 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.2.1 US
10.2.1.1 US to dominate North American genotyping assay market during forecast period
TABLE 203 US: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 204 US: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 205 US: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 206 US: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 207 US: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 208 US: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 209 US: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 210 US: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 211 US: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Increasing government initiatives and funding for genomics research to drive market
TABLE 212 CANADA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 213 CANADA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 214 CANADA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 215 CANADA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 216 CANADA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 217 CANADA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 218 CANADA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 219 CANADA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 220 CANADA: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.2.3 NORTH AMERICA: RECESSION IMPACT
10.3 EUROPE
TABLE 221 EUROPE: GENOTYPING ASSAY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 222 EUROPE: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 223 EUROPE: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 224 EUROPE: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 225 EUROPE: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 226 EUROPE: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 227 EUROPE: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 228 EUROPE: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 229 EUROPE: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 230 EUROPE: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Higher healthcare spending and improved R&D for NGS-based diagnostic tests to augment market growth
TABLE 231 GERMANY: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 232 GERMANY: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 233 GERMANY: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 234 GERMANY: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 235 GERMANY: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 236 GERMANY: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 237 GERMANY: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 238 GERMANY: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 239 GERMANY: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.2 UK
10.3.2.1 Increasing biotechnology innovation centers and growing government support to fuel market growth
TABLE 240 UK: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 241 UK: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 242 UK: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 243 UK: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 244 UK: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 245 UK: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 246 UK: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 247 UK: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 248 UK: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Rising government investments in genomics to boost market growth
TABLE 249 FRANCE: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 250 FRANCE: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 251 FRANCE: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 252 FRANCE: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 253 FRANCE: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 254 FRANCE: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 255 FRANCE: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 256 FRANCE: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 257 FRANCE: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.4 ITALY
10.3.4.1 Favorable funding scenario in genomics research to support market growth
TABLE 258 ITALY: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 259 ITALY: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 260 ITALY: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 261 ITALY: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 262 ITALY: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 263 ITALY: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 264 ITALY: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 265 ITALY: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 266 ITALY: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 Increased R&D funding by government to spur market growth
TABLE 267 SPAIN: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 268 SPAIN: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 269 SPAIN: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 270 SPAIN: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 271 SPAIN: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 272 SPAIN: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 273 SPAIN: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 274 SPAIN: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 275 SPAIN: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 276 REST OF EUROPE: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 277 REST OF EUROPE: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 278 REST OF EUROPE: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 279 REST OF EUROPE: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 280 REST OF EUROPE: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 281 REST OF EUROPE: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 282 REST OF EUROPE: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 283 REST OF EUROPE: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 284 REST OF EUROPE: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.7 EUROPE: RECESSION IMPACT
10.4 ASIA PACIFIC
FIGURE 41 ASIA PACIFIC: GENOTYPING ASSAY MARKET SNAPSHOT
TABLE 285 ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 286 ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 287 ASIA PACIFIC: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 288 ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 289 ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 290 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 291 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 292 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 293 ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 294 ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.4.1 CHINA
10.4.1.1 Low cost of sequencing procedures and favorable government initiatives to fuel market growth
TABLE 295 CHINA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 296 CHINA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 297 CHINA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 298 CHINA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 299 CHINA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 300 CHINA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 301 CHINA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 302 CHINA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 303 CHINA: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Launch of technologically advanced sequencing platforms to drive market
TABLE 304 JAPAN: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 305 JAPAN: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 306 JAPAN: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 307 JAPAN: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 308 JAPAN: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 309 JAPAN: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 310 JAPAN: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 311 JAPAN: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 312 JAPAN: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Increasing research on gene expression therapies and decreasing cost of sequencing to augment market growth
TABLE 313 INDIA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 314 INDIA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 315 INDIA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 316 INDIA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 317 INDIA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 318 INDIA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 319 INDIA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 320 INDIA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 321 INDIA: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 322 REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 323 REST OF ASIA PACIFIC: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 324 REST OF ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 325 REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 326 REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 327 REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 328 REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 329 REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 330 REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.4.5 ASIA PACIFIC: RECESSION IMPACT
10.5 LATIN AMERICA
TABLE 331 LATIN AMERICA: GENOTYPING ASSAY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 332 LATIN AMERICA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 333 LATIN AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 334 LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 335 LATIN AMERICA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 336 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 337 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 338 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 339 LATIN AMERICA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 340 LATIN AMERICA: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.5.1 BRAZIL
10.5.1.1 Establishment of manufacturing facilities by key players to propel market growth
TABLE 341 BRAZIL: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 342 BRAZIL: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 343 BRAZIL: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 344 BRAZIL: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 345 BRAZIL: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 346 BRAZIL: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 347 BRAZIL: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 348 BRAZIL: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 349 BRAZIL: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.5.2 MEXICO
10.5.2.1 Favorable trade agreements and increased government support to boost market growth
TABLE 350 MEXICO: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 351 MEXICO: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 352 MEXICO: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 353 MEXICO: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 354 MEXICO: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 355 MEXICO: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 356 MEXICO: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 357 MEXICO: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 358 MEXICO: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.5.3 REST OF LATIN AMERICA
TABLE 359 REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 360 REST OF LATIN AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 361 REST OF LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 362 REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 363 REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 364 REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 365 REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 366 REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 367 REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.5.4 LATIN AMERICA: RECESSION IMPACT
10.6 MIDDLE EAST & AFRICA
10.6.1 INCREASING ADOPTION OF GENETIC TESTING AND RISING INCIDENCE OF CANCER TO DRIVE MARKET
TABLE 368 MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 369 MIDDLE EAST & AFRICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 370 MIDDLE EAST & AFRICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 371 MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 372 MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 373 MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 374 MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 375 MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 376 MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
10.7 GCC COUNTRIES
10.7.1 IMPROVED HEALTHCARE INFRASTRUCTURE AND RISE IN LIFESTYLE-RELATED DISEASES TO FUEL MARKET GROWTH
TABLE 377 GCC COUNTRIES: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 378 GCC COUNTRIES: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 379 GCC COUNTRIES: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 380 GCC COUNTRIES: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 381 GCC COUNTRIES: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 382 GCC COUNTRIES: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 383 GCC COUNTRIES: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 384 GCC COUNTRIES: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 385 GCC COUNTRIES: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.7.2 GCC COUNTRIES: RECESSION IMPACT
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN GENOTYPING ASSAY MARKET
TABLE 386 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN GENOTYPING ASSAY MARKET
11.3 REVENUE ANALYSIS
FIGURE 42 REVENUE ANALYSIS OF KEY PLAYERS IN GENOTYPING ASSAY MARKET (2021–2023)
11.4 MARKET SHARE ANALYSIS
FIGURE 43 MARKET SHARE ANALYSIS OF KEY PLAYERS IN GENOTYPING ASSAY MARKET (2023)
TABLE 387 GENOTYPING ASSAY MARKET: DEGREE OF COMPETITION
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 44 GENOTYPING ASSAY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
11.5.5.1 Company footprint
FIGURE 45 GENOTYPING ASSAY MARKET: COMPANY FOOTPRINT
11.5.5.2 Product & service footprint
TABLE 388 GENOTYPING ASSAY MARKET: PRODUCT & SERVICE FOOTPRINT
11.5.5.3 Technology footprint
TABLE 389 GENOTYPING ASSAY MARKET: TECHNOLOGY FOOTPRINT
11.5.5.4 Application footprint
TABLE 390 GENOTYPING ASSAY MARKET: APPLICATION FOOTPRINT
11.5.5.5 Region footprint
TABLE 391 GENOTYPING ASSAY MARKET: REGION FOOTPRINT
11.6 COMPETITIVE EVALUATION MATRIX: STARTUPS/SMES, 2023
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
FIGURE 46 GENOTYPING ASSAY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
TABLE 392 GENOTYPING ASSAY MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 393 GENOTYPING ASSAY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
11.7 VALUATION & FINANCIAL METRICS
FIGURE 47 EV/EBITDA OF KEY VENDORS
FIGURE 48 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
11.8 BRAND/PRODUCT COMPARISON
FIGURE 49 GENOTYPING ASSAY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
11.8.1 THERMO FISHER SCIENTIFIC INC.
11.8.2 AGILENT TECHNOLOGIES, INC.
11.8.3 QIAGEN
11.8.4 ILLUMINA, INC.
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES, DEVELOPMENTS, AND APPROVALS
TABLE 394 GENOTYPING ASSAY MARKET: PRODUCT LAUNCHES, DEVELOPMENTS, AND APPROVALS, JANUARY 2020–MARCH 2024
11.9.2 DEALS
TABLE 395 GENOTYPING ASSAY MARKET: DEALS, JANUARY 2020–MARCH 2024
12 COMPANY PROFILES
12.1 KEY PLAYERS
(Business overview, Products/Services/Solutions offered, Recent developments, MnM view, Key strengths, Strategic choices, and Weaknesses and Competitive threats)*
12.1.1 THERMO FISHER SCIENTIFIC INC.
TABLE 396 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
FIGURE 50 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
TABLE 397 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 398 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2020–MARCH 2024
TABLE 399 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2020–MARCH 2024
12.1.2 ILLUMINA, INC.
TABLE 400 ILLUMINA, INC.: COMPANY OVERVIEW
FIGURE 51 ILLUMINA, INC.: COMPANY SNAPSHOT (2023)
TABLE 401 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 402 ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2020–MARCH 2024
TABLE 403 ILLUMINA, INC.: DEALS, JANUARY 2020–MARCH 2024
TABLE 404 ILLUMINA, INC.: EXPANSIONS, JANUARY 2020–MARCH 2024
12.1.3 DANAHER CORPORATION
TABLE 405 DANAHER CORPORATION: COMPANY OVERVIEW
FIGURE 52 DANAHER CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 406 DANAHER CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 407 DANAHER CORPORATION: PRODUCT LAUNCHES, JANUARY 2020–MARCH 2024
TABLE 408 DANAHER CORPORATION: DEALS, JANUARY 2020–MARCH 2024
12.1.4 QIAGEN
TABLE 409 QIAGEN: COMPANY OVERVIEW
FIGURE 53 QIAGEN: COMPANY SNAPSHOT (2023)
TABLE 410 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 411 QIAGEN: PRODUCT LAUNCHES AND DEVELOPMENTS, JANUARY 2020–MARCH 2024
TABLE 412 QIAGEN: DEALS, JANUARY 2020–MARCH 2024
12.1.5 EUROFINS SCIENTIFIC
TABLE 413 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
FIGURE 54 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2023)
TABLE 414 EUROFINS SCIENTIFIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 415 EUROFINS SCIENTIFIC: PRODUCT AND SERVICE LAUNCHES, JANUARY 2020–MARCH 2024
TABLE 416 EUROFINS SCIENTIFIC: DEALS, JANUARY 2020–MARCH 2024
12.1.6 F. HOFFMANN-LA ROCHE LTD.
TABLE 417 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
FIGURE 55 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
TABLE 418 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 419 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES, JANUARY 2020–MARCH 2024
TABLE 420 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2020–MARCH 2024
12.1.7 AGILENT TECHNOLOGIES, INC.
TABLE 421 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
FIGURE 56 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
TABLE 422 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 423 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2020–MARCH 2024
12.1.8 BIO-RAD LABORATORIES, INC.
TABLE 424 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
FIGURE 57 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)
TABLE 425 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.1.9 MERCK KGAA
TABLE 426 MERCK KGAA: COMPANY OVERVIEW
FIGURE 58 MERCK KGAA: COMPANY SNAPSHOT (2023)
TABLE 427 MERCK KGAA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.1.10 STANDARD BIOTOOLS
TABLE 428 STANDARD BIOTOOLS: COMPANY OVERVIEW
FIGURE 59 STANDARD BIOTOOLS: COMPANY SNAPSHOT (2023)
TABLE 429 STANDARD BIOTOOLS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.2 OTHER PLAYERS
12.2.1 REVVITY
TABLE 430 REVVITY: COMPANY OVERVIEW
12.2.2 PACBIO
TABLE 431 PACBIO: COMPANY OVERVIEW
12.2.3 LUMINEX CORPORATION (A DIASORIN COMPANY)
TABLE 432 LUMINEX CORPORATION (A DIASORIN COMPANY): COMPANY OVERVIEW
12.2.4 OXFORD NANOPORE TECHNOLOGIES PLC
TABLE 433 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY OVERVIEW
12.2.5 GENEWIZ, INC.
TABLE 434 GENEWIZ, INC.: COMPANY OVERVIEW
12.2.6 TAKARA BIO INC.
TABLE 435 TAKARA BIO INC.: COMPANY OVERVIEW
12.2.7 BGI GROUP
TABLE 436 BGI GROUP: COMPANY OVERVIEW
12.2.8 PROMEGA CORPORATION
TABLE 437 PROMEGA CORPORATION: COMPANY OVERVIEW
12.2.9 NOVOGENE CO., LTD.
TABLE 438 NOVOGENE CO., LTD.: COMPANY OVERVIEW
12.2.10 GENSCRIPT
TABLE 439 GENSCRIPT: COMPANY OVERVIEW
12.2.11 NEW ENGLAND BIOLABS
TABLE 440 NEW ENGLAND BIOLABS: COMPANY OVERVIEW
12.2.12 PARAGON GENOMICS, INC.
TABLE 441 PARAGON GENOMICS, INC.: COMPANY OVERVIEW
12.2.13 NEOGENOMICS LABORATORIES
TABLE 442 NEOGENOMICS LABORATORIES: COMPANY OVERVIEW
12.2.14 TECAN TRADING AG
TABLE 443 TECAN TRADING AG: COMPANY OVERVIEW
12.2.15 GENOTYPIC TECHNOLOGY PVT. LTD.
TABLE 444 GENOTYPIC TECHNOLOGY PVT. LTD.: COMPANY OVERVIEW
*Details on Business overview, Products/Services/Solutions offered, Recent developments, MnM view, Key strengths, Strategic choices, and Weaknesses and Competitive threats might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
TABLE 1 GENOTYPING ASSAY MARKET: INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 SEGMENTS COVERED
FIGURE 1 GENOTYPING ASSAY MARKET: SEGMENTS COVERED
1.3.2 REGIONS COVERED
FIGURE 2 GENOTYPING ASSAY MARKET: REGIONS COVERED
1.3.3 YEARS CONSIDERED
FIGURE 3 GENOTYPING ASSAY MARKET: YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
1.5.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 4 GENOTYPING ASSAY MARKET: RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key secondary sources
2.1.1.2 Key data from secondary sources
FIGURE 5 KEY DATA FROM SECONDARY SOURCES
2.1.1.3 Objectives of secondary research
2.1.2 PRIMARY DATA
2.1.2.1 Key primary sources: Demand and supply sides
FIGURE 6 KEY PRIMARY SOURCES: DEMAND AND SUPPLY SIDES
2.1.2.2 Objectives of primary research
2.1.2.3 Key data from primary sources
TABLE 2 GENOTYPING ASSAY MARKET: KEY DATA FROM PRIMARY SOURCES
2.1.2.4 Insights from primary experts
FIGURE 7 GENOTYPING ASSAY MARKET: KEY INSIGHTS FROM PRIMARY EXPERTS
2.1.2.5 Breakdown of primaries
FIGURE 8 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
FIGURE 9 BREAKDOWN OF PRIMARIES: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Company revenue estimation approach
FIGURE 10 COMPANY REVENUE ESTIMATION APPROACH
2.2.1.2 Company presentations and primary interviews
2.2.1.3 Growth forecasts
2.2.1.4 CAGR projections
FIGURE 11 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.2.2 TOP-DOWN APPROACH
FIGURE 12 GENOTYPING ASSAY MARKET: TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 13 GENOTYPING ASSAY MARKET: DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 STUDY ASSUMPTIONS
2.6 GROWTH RATE ASSUMPTIONS
2.7 RISK ASSESSMENT
TABLE 3 GENOTYPING ASSAY MARKET: RISK ASSESSMENT
2.8 RESEARCH LIMITATIONS
2.9 IMPACT OF ECONOMIC RECESSION ON GENOTYPING ASSAY MARKET
3 EXECUTIVE SUMMARY
FIGURE 14 GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION)
FIGURE 15 GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 16 GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 17 GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
FIGURE 18 GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 19 GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 20 GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 21 GENOTYPING ASSAY MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
FIGURE 22 GENOTYPING ASSAY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 23 GENOTYPING ASSAY MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)
4 PREMIUM INSIGHTS
4.1 GENOTYPING ASSAY MARKET OVERVIEW
FIGURE 24 TECHNOLOGICAL ADVANCEMENTS AND REDUCED PRICES OF DNA SEQUENCING TO DRIVE MARKET
4.2 GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029
FIGURE 25 REAGENTS & KITS TO COMMAND LARGEST MARKET SHARE DURING FORECAST PERIOD
4.3 GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2024 VS. 2029
FIGURE 26 POLYMERASE CHAIN REACTION TO POSSESS LARGEST MARKET SHARE BETWEEN 2024 AND 2029
4.4 GENOTYPING ASSAY MARKET, BY APPLICATION, 2024 VS. 2029
FIGURE 27 PHARMACOGENOMICS TO ACCOUNT FOR LARGEST MARKET SHARE DURING STUDY PERIOD
4.5 GENOTYPING ASSAY MARKET, BY END USER, 2024 VS. 2029
FIGURE 28 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO COMMAND LARGEST MARKET SHARE FROM 2024 TO 2029
4.6 GENOTYPING ASSAY MARKET: REGIONAL GROWTH OPPORTUNITIES (2024–2029)
FIGURE 29 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 30 GENOTYPING ASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Technological advancements and reduced prices of DNA sequencing
FIGURE 31 COST OF HUMAN WHOLE-GENOME SEQUENCING, 2002–2022
5.2.1.2 Increasing incidence of genetic diseases and rising use of personalized medicines
5.2.1.3 Growing importance and use of genotyping in drug discovery and development
5.2.1.4 Increasing demand for bioinformatics solutions in data analysis
5.2.2 RESTRAINTS
5.2.2.1 High manufacturing, installation, and maintenance costs of genotyping instruments
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing use of genomics in animal genetics and agricultural biotechnology
5.2.4 CHALLENGES
5.2.4.1 Lack of adequate data management in genomics research
5.2.4.2 Dearth of trained healthcare personnel for genomic sequencing data analysis
5.3 PRICING ANALYSIS
5.3.1 PRICING ANALYSIS FOR GENOTYPING ASSAY PRODUCTS, 2021–2023
TABLE 4 PRICING ANALYSIS TREND FOR GENOTYPING ASSAY PRODUCTS, 2021–2023
5.3.2 AVERAGE SELLING PRICE OF GENOTYPING ASSAY PRODUCTS, BY REGION, 2021–2023
TABLE 5 AVERAGE SELLING PRICE OF GENOTYPING ASSAY PRODUCTS, BY REGION, 2021–2023
5.4 PATENT ANALYSIS
FIGURE 32 PATENT APPLICATIONS FOR GENOTYPING ASSAY (NEXT-GENERATION SEQUENCING) MARKET, JANUARY 2012–MARCH 2023
TABLE 6 INDICATIVE LIST OF PATENTS IN GENOTYPING ASSAY (NEXT-GENERATION SEQUENCING) MARKET
5.5 VALUE CHAIN ANALYSIS
FIGURE 33 GENOTYPING ASSAY MARKET: VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.6.1 PROMINENT COMPANIES
5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES
5.6.3 END USERS
FIGURE 34 GENOTYPING ASSAY MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
FIGURE 35 GENOTYPING ASSAY MARKET: ECOSYSTEM MAP
5.7.1 ROLE IN ECOSYSTEM
TABLE 7 GENOTYPING ASSAY MARKET: ROLE IN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
FIGURE 36 GENOTYPING ASSAY MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 8 GENOTYPING ASSAY MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF SUPPLIERS
5.8.4 BARGAINING POWER OF BUYERS
5.8.5 INTENSITY OF COMPETITIVE RIVALRY
5.9 KEY STAKEHOLDERS AND BUYING CRITERIA
5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 37 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
TABLE 9 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
5.9.2 KEY BUYING CRITERIA
FIGURE 38 KEY BUYING CRITERIA FOR GENOTYPING ASSAYS
TABLE 10 KEY BUYING CRITERIA FOR GENOTYPING ASSAYS
5.10 REGULATORY ANALYSIS
5.10.1 REGULATORY LANDSCAPE
5.10.1.1 North America
5.10.1.1.1 US
TABLE 11 US FDA: MEDICAL DEVICE CLASSIFICATION
TABLE 12 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
5.10.1.1.2 Canada
5.10.1.2 Europe
5.10.1.3 Asia Pacific
5.10.1.3.1 China
TABLE 13 CHINA: CLASSIFICATION OF MEDICAL DEVICES
5.10.1.3.2 Japan
5.10.1.3.3 India
5.10.1.4 Latin America
5.10.1.5 Middle East
5.11 TRADE ANALYSIS
5.11.1 IMPORT DATA FOR PCR ANALYZERS (HS CODE 3822)
TABLE 14 IMPORT DATA FOR PCR ANALYZERS (HS CODE 3822), BY COUNTRY, 2017–2021 (USD)
5.11.2 EXPORT DATA FOR PCR ANALYZERS (HS CODE 3822)
TABLE 15 EXPORT DATA FOR PCR ANALYZERS (HS CODE 3822), BY COUNTRY, 2017–2021 (USD)
5.12 TECHNOLOGY ANALYSIS
5.12.1 KEY TECHNOLOGIES
5.12.1.1 Polymerase chain reaction
5.12.1.2 Next-generation sequencing
5.12.2 COMPLEMENTARY TECHNOLOGIES
5.12.2.1 CRISPR-based perturbational
5.12.3 ADJACENT TECHNOLOGIES
5.12.3.1 Single-cell RNA sequencing
5.13 KEY CONFERENCES AND EVENTS, 2024–2025
TABLE 16 GENOTYPING ASSAY MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS, JANUARY 2024–DECEMBER 2025
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 39 REVENUE SHIFT IN GENOTYPING ASSAY MARKET
5.15 CASE STUDY ANALYSIS
5.15.1 DIGITAL PCR FOR GENOTYPE QUANTIFICATION IN PASTA PRODUCTION CHAIN
5.16 INVESTMENT & FUNDING SCENARIO
6 GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
TABLE 17 GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
6.2 REAGENTS & KITS
6.2.1 INCREASING VOLUME OF GENOTYPING TESTS TO DRIVE MARKET
TABLE 18 GENOTYPING ASSAY REAGENTS & KITS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 19 NORTH AMERICA: GENOTYPING ASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 20 EUROPE: GENOTYPING ASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 21 ASIA PACIFIC: GENOTYPING ASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 22 LATIN AMERICA: GENOTYPING ASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.3 GENOTYPING SERVICES
6.3.1 RISING DEMAND FOR SEQUENCING FROM HOSPITALS AND PHARMACEUTICAL COMPANIES TO PROPEL MARKET GROWTH
TABLE 23 GENOTYPING ASSAY SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 24 NORTH AMERICA: GENOTYPING ASSAY SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 25 EUROPE: GENOTYPING ASSAY SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 26 ASIA PACIFIC: GENOTYPING ASSAY SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 27 LATIN AMERICA: GENOTYPING ASSAY SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.4 INSTRUMENTS
TABLE 28 GENOTYPING ASSAY INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 29 NORTH AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 30 EUROPE: GENOTYPING ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 31 ASIA PACIFIC: GENOTYPING ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 32 LATIN AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 33 GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
6.4.1 SEQUENCERS & AMPLIFIERS
6.4.1.1 Decreasing cost of DNA sequencing procedures to aid market growth
TABLE 34 GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 35 NORTH AMERICA: GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 36 EUROPE: GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 37 ASIA PACIFIC: GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 38 LATIN AMERICA: GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.4.2 ANALYZERS
6.4.2.1 Technological advancements in high-throughput analyzers to support market growth
TABLE 39 GENOTYPING ASSAY ANALYZERS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 40 NORTH AMERICA: GENOTYPING ASSAY ANALYZERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 41 EUROPE: GENOTYPING ASSAY ANALYZERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 42 ASIA PACIFIC: GENOTYPING ASSAY ANALYZERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 43 LATIN AMERICA: GENOTYPING ASSAY ANALYZERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.5 BIOINFORMATICS
TABLE 44 GENOTYPING ASSAY BIOINFORMATICS MARKET, BY REGION, 2022–2029, (USD MILLION)
TABLE 45 NORTH AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 46 EUROPE: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 47 ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 48 LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 49 GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
6.5.1 SOFTWARE
6.5.1.1 High volume of sequencing and microarray tests to augment segment growth
TABLE 50 GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 51 NORTH AMERICA: GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 52 EUROPE: GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 53 ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 54 LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.5.2 SERVICES
6.5.2.1 Increasing public-private funding to support segment growth
TABLE 55 GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 56 NORTH AMERICA: GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 57 EUROPE: GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 58 ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 59 LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7 GENOTYPING ASSAY MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 60 GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
7.2 POLYMERASE CHAIN REACTION
TABLE 61 COMPARATIVE STUDY: REAL-TIME POLYMERASE CHAIN REACTION VS. DIGITAL POLYMERASE CHAIN REACTION
TABLE 62 GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 63 GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2022–2029 (USD MILLION)
TABLE 64 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 65 EUROPE: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 66 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 67 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
7.2.1 REAL-TIME POLYMERASE CHAIN REACTION
7.2.1.1 Continuous automation of laboratory techniques to propel market growth
TABLE 68 KEY REAL-TIME POLYMERASE CHAIN REACTION PRODUCTS
TABLE 69 REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 70 NORTH AMERICA: REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 71 EUROPE: REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 72 ASIA PACIFIC: REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 73 LATIN AMERICA: REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7.2.2 DIGITAL POLYMERASE CHAIN REACTION
7.2.2.1 High cost of instruments and lack of knowledge among end users to limit market growth
TABLE 74 KEY DIGITAL POLYMERASE CHAIN REACTION PRODUCTS
TABLE 75 DIGITAL POLYMERASE CHAIN REACTION MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 76 NORTH AMERICA: DIGITAL POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 77 EUROPE: DIGITAL POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 78 ASIA PACIFIC: DIGITAL POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 79 LATIN AMERICA: DIGITAL POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7.3 MICROARRAYS
7.3.1 HIGH DEMAND FOR PERSONALIZED MEDICINES TO DRIVE MARKET
TABLE 80 KEY MICROARRAYS
TABLE 81 GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY REGION, 2022–2029 (USD MILLION)
TABLE 82 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 83 EUROPE: GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 84 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 85 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY COUNTRY, 2022–2029 (USD MILLION)
7.4 SEQUENCING
TABLE 86 GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 87 GENOTYPING ASSAY MARKET FOR SEQUENCING, BY REGION, 2022–2029 (USD MILLION)
TABLE 88 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 89 EUROPE: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 90 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 91 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
7.4.1 NEXT-GENERATION SEQUENCING
7.4.1.1 Higher speed and better accuracy to fuel segment growth
TABLE 92 KEY NEXT-GENERATION SEQUENCING PRODUCTS
TABLE 93 NEXT-GENERATION SEQUENCING MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 94 NORTH AMERICA: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 95 EUROPE: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 96 ASIA PACIFIC: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 97 LATIN AMERICA: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7.4.2 PYROSEQUENCING
7.4.2.1 Growing need for genotyping difficult assays with accurate results to augment growth
TABLE 98 KEY PYROSEQUENCING PRODUCTS
TABLE 99 PYROSEQUENCING MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 100 NORTH AMERICA: PYROSEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 101 EUROPE: PYROSEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 102 ASIA PACIFIC: PYROSEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 103 LATIN AMERICA: PYROSEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7.4.3 SANGER SEQUENCING
7.4.3.1 Increasing use in small-scale experiments to boost segment growth
TABLE 104 KEY SANGER SEQUENCING PRODUCTS
TABLE 105 SANGER SEQUENCING MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 106 NORTH AMERICA: SANGER SEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 107 EUROPE: SANGER SEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 108 ASIA PACIFIC: SANGER SEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 109 LATIN AMERICA: SANGER SEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7.5 CAPILLARY ELECTROPHORESIS
TABLE 110 GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 111 GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY REGION, 2022–2029 (USD MILLION)
TABLE 112 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 113 EUROPE: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 114 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 115 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2022–2029 (USD MILLION)
7.5.1 AMPLIFIED FRAGMENT LENGTH POLYMORPHISM
7.5.1.1 Increasing use in determining genetic differences to drive segment
TABLE 116 AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 117 NORTH AMERICA: AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 118 EUROPE: AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 119 ASIA PACIFIC: AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 120 LATIN AMERICA: AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7.5.2 RESTRICTION FRAGMENT LENGTH POLYMORPHISM
7.5.2.1 Rising demand in forensics and agricultural institutions to support market growth
TABLE 121 KEY RESTRICTION FRAGMENT LENGTH POLYMORPHISM PRODUCTS
TABLE 122 RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 123 NORTH AMERICA: RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 124 EUROPE: RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 125 ASIA PACIFIC: RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 126 LATIN AMERICA: RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7.5.3 SINGLE-STRAND CONFORMATION POLYMORPHISM
7.5.3.1 Increasing applications in virology to boost segment growth
TABLE 127 KEY SINGLE-STRAND CONFORMATION POLYMORPHISM PRODUCTS
TABLE 128 SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 129 NORTH AMERICA: SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 130 EUROPE: SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 131 ASIA PACIFIC: SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 132 LATIN AMERICA: SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7.6 MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY
7.6.1 INCREASING APPLICATIONS IN CLINICAL DIAGNOSTICS AND PHARMACOGENOMICS TO AID MARKET GROWTH
TABLE 133 KEY MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT PRODUCTS
TABLE 134 GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY, BY REGION, 2022–2029 (USD MILLION)
TABLE 135 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 136 EUROPE: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 137 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 138 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
7.7 OTHER TECHNOLOGIES
TABLE 139 OTHER GENOTYPING TECHNOLOGIES
TABLE 140 GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 141 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 142 EUROPE: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 143 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 144 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
8 GENOTYPING ASSAY MARKET, BY APPLICATION
8.1 INTRODUCTION
TABLE 145 GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
8.2 PHARMACOGENOMICS
8.2.1 GROWING DEMAND FOR STUDYING ADVERSE DRUG REACTIONS IN CLINICAL TRIALS TO DRIVE MARKET
TABLE 146 GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY REGION, 2022–2029 (USD MILLION)
TABLE 147 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 148 EUROPE: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 149 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 150 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY, 2022–2029 (USD MILLION)
8.3 DIAGNOSTICS & PERSONALIZED MEDICINES
8.3.1 INCREASING FOCUS ON DEVELOPING DIAGNOSTICS TESTS THROUGH RAPID GENOTYPING TO AID MARKET GROWTH
TABLE 151 GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINES, BY REGION, 2022–2029 (USD MILLION)
TABLE 152 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 153 EUROPE: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 154 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 155 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINES, BY COUNTRY, 2022–2029 (USD MILLION)
8.4 ANIMAL GENETICS
8.4.1 NEED TO INCREASE LIVESTOCK POPULATION TO PROPEL MARKET GROWTH
TABLE 156 GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY REGION, 2022–2029 (USD MILLION)
TABLE 157 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 158 EUROPE: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 159 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 160 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY COUNTRY, 2022–2029 (USD MILLION)
8.5 AGRICULTURAL BIOTECHNOLOGY
8.5.1 INCREASING USE OF PLANT GENOTYPING IN RESEARCH LABORATORIES AND GREENHOUSES TO FUEL MARKET GROWTH
TABLE 161 GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY REGION, 2022–2029 (USD MILLION)
TABLE 162 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 163 EUROPE: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 164 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 165 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
8.6 OTHER APPLICATIONS
TABLE 166 GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 167 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 168 EUROPE: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 169 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 170 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
9 GENOTYPING ASSAY MARKET, BY END USER
9.1 INTRODUCTION
TABLE 171 GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
9.2.1 RISING DEMAND FOR PHARMACOGENOMICS IN DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET
TABLE 172 GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 173 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029(USD MILLION)
TABLE 174 EUROPE: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029(USD MILLION)
TABLE 175 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 176 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
9.3 DIAGNOSTIC LABORATORIES
9.3.1 GROWING PREFERENCE FOR PERSONALIZED MEDICINES TO AUGMENT MARKET GROWTH
TABLE 177 GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 178 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029(USD MILLION)
TABLE 179 EUROPE: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 180 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 181 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
9.4 ACADEMIC & RESEARCH INSTITUTES
9.4.1 INCREASING INDUSTRY-ACADEMIA COLLABORATIONS FOR DRUG DEVELOPMENT TO SUPPORT MARKET GROWTH
TABLE 182 GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION)
TABLE 183 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 184 EUROPE: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 185 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 186 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
9.5 OTHER END USERS
TABLE 187 GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
TABLE 188 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 189 EUROPE: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 190 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 191 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
10 GENOTYPING ASSAY MARKET, BY REGION
10.1 INTRODUCTION
TABLE 192 GENOTYPING ASSAY MARKET, BY REGION, 2022–2029 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 40 NORTH AMERICA: GENOTYPING ASSAY MARKET SNAPSHOT
TABLE 193 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 194 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 195 NORTH AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 196 NORTH AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 197 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 198 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 199 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 200 NORTH AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 201 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 202 NORTH AMERICA: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.2.1 US
10.2.1.1 US to dominate North American genotyping assay market during forecast period
TABLE 203 US: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 204 US: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 205 US: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 206 US: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 207 US: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 208 US: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 209 US: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 210 US: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 211 US: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Increasing government initiatives and funding for genomics research to drive market
TABLE 212 CANADA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 213 CANADA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 214 CANADA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 215 CANADA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 216 CANADA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 217 CANADA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 218 CANADA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 219 CANADA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 220 CANADA: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.2.3 NORTH AMERICA: RECESSION IMPACT
10.3 EUROPE
TABLE 221 EUROPE: GENOTYPING ASSAY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 222 EUROPE: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 223 EUROPE: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 224 EUROPE: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 225 EUROPE: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 226 EUROPE: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 227 EUROPE: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 228 EUROPE: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 229 EUROPE: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 230 EUROPE: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Higher healthcare spending and improved R&D for NGS-based diagnostic tests to augment market growth
TABLE 231 GERMANY: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 232 GERMANY: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 233 GERMANY: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 234 GERMANY: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 235 GERMANY: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 236 GERMANY: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 237 GERMANY: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 238 GERMANY: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 239 GERMANY: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.2 UK
10.3.2.1 Increasing biotechnology innovation centers and growing government support to fuel market growth
TABLE 240 UK: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 241 UK: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 242 UK: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 243 UK: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 244 UK: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 245 UK: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 246 UK: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 247 UK: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 248 UK: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Rising government investments in genomics to boost market growth
TABLE 249 FRANCE: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 250 FRANCE: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 251 FRANCE: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 252 FRANCE: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 253 FRANCE: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 254 FRANCE: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 255 FRANCE: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 256 FRANCE: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 257 FRANCE: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.4 ITALY
10.3.4.1 Favorable funding scenario in genomics research to support market growth
TABLE 258 ITALY: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 259 ITALY: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 260 ITALY: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 261 ITALY: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 262 ITALY: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 263 ITALY: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 264 ITALY: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 265 ITALY: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 266 ITALY: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 Increased R&D funding by government to spur market growth
TABLE 267 SPAIN: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 268 SPAIN: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 269 SPAIN: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 270 SPAIN: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 271 SPAIN: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 272 SPAIN: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 273 SPAIN: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 274 SPAIN: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 275 SPAIN: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 276 REST OF EUROPE: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 277 REST OF EUROPE: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 278 REST OF EUROPE: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 279 REST OF EUROPE: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 280 REST OF EUROPE: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 281 REST OF EUROPE: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 282 REST OF EUROPE: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 283 REST OF EUROPE: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 284 REST OF EUROPE: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.3.7 EUROPE: RECESSION IMPACT
10.4 ASIA PACIFIC
FIGURE 41 ASIA PACIFIC: GENOTYPING ASSAY MARKET SNAPSHOT
TABLE 285 ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 286 ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 287 ASIA PACIFIC: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 288 ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 289 ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 290 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 291 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 292 ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 293 ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 294 ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.4.1 CHINA
10.4.1.1 Low cost of sequencing procedures and favorable government initiatives to fuel market growth
TABLE 295 CHINA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 296 CHINA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 297 CHINA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 298 CHINA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 299 CHINA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 300 CHINA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 301 CHINA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 302 CHINA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 303 CHINA: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Launch of technologically advanced sequencing platforms to drive market
TABLE 304 JAPAN: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 305 JAPAN: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 306 JAPAN: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 307 JAPAN: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 308 JAPAN: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 309 JAPAN: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 310 JAPAN: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 311 JAPAN: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 312 JAPAN: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Increasing research on gene expression therapies and decreasing cost of sequencing to augment market growth
TABLE 313 INDIA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 314 INDIA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 315 INDIA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 316 INDIA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 317 INDIA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 318 INDIA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 319 INDIA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 320 INDIA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 321 INDIA: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 322 REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 323 REST OF ASIA PACIFIC: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 324 REST OF ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 325 REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 326 REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 327 REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 328 REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 329 REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 330 REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.4.5 ASIA PACIFIC: RECESSION IMPACT
10.5 LATIN AMERICA
TABLE 331 LATIN AMERICA: GENOTYPING ASSAY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 332 LATIN AMERICA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 333 LATIN AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 334 LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 335 LATIN AMERICA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 336 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 337 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 338 LATIN AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 339 LATIN AMERICA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 340 LATIN AMERICA: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.5.1 BRAZIL
10.5.1.1 Establishment of manufacturing facilities by key players to propel market growth
TABLE 341 BRAZIL: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 342 BRAZIL: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 343 BRAZIL: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 344 BRAZIL: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 345 BRAZIL: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 346 BRAZIL: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 347 BRAZIL: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 348 BRAZIL: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 349 BRAZIL: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.5.2 MEXICO
10.5.2.1 Favorable trade agreements and increased government support to boost market growth
TABLE 350 MEXICO: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 351 MEXICO: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 352 MEXICO: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 353 MEXICO: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 354 MEXICO: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 355 MEXICO: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 356 MEXICO: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 357 MEXICO: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 358 MEXICO: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.5.3 REST OF LATIN AMERICA
TABLE 359 REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 360 REST OF LATIN AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 361 REST OF LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 362 REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 363 REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 364 REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 365 REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 366 REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 367 REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.5.4 LATIN AMERICA: RECESSION IMPACT
10.6 MIDDLE EAST & AFRICA
10.6.1 INCREASING ADOPTION OF GENETIC TESTING AND RISING INCIDENCE OF CANCER TO DRIVE MARKET
TABLE 368 MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 369 MIDDLE EAST & AFRICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 370 MIDDLE EAST & AFRICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 371 MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 372 MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 373 MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 374 MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 375 MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 376 MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
10.7 GCC COUNTRIES
10.7.1 IMPROVED HEALTHCARE INFRASTRUCTURE AND RISE IN LIFESTYLE-RELATED DISEASES TO FUEL MARKET GROWTH
TABLE 377 GCC COUNTRIES: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 378 GCC COUNTRIES: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 379 GCC COUNTRIES: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 380 GCC COUNTRIES: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 381 GCC COUNTRIES: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)
TABLE 382 GCC COUNTRIES: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)
TABLE 383 GCC COUNTRIES: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 384 GCC COUNTRIES: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 385 GCC COUNTRIES: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)
10.7.2 GCC COUNTRIES: RECESSION IMPACT
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN GENOTYPING ASSAY MARKET
TABLE 386 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN GENOTYPING ASSAY MARKET
11.3 REVENUE ANALYSIS
FIGURE 42 REVENUE ANALYSIS OF KEY PLAYERS IN GENOTYPING ASSAY MARKET (2021–2023)
11.4 MARKET SHARE ANALYSIS
FIGURE 43 MARKET SHARE ANALYSIS OF KEY PLAYERS IN GENOTYPING ASSAY MARKET (2023)
TABLE 387 GENOTYPING ASSAY MARKET: DEGREE OF COMPETITION
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 44 GENOTYPING ASSAY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
11.5.5.1 Company footprint
FIGURE 45 GENOTYPING ASSAY MARKET: COMPANY FOOTPRINT
11.5.5.2 Product & service footprint
TABLE 388 GENOTYPING ASSAY MARKET: PRODUCT & SERVICE FOOTPRINT
11.5.5.3 Technology footprint
TABLE 389 GENOTYPING ASSAY MARKET: TECHNOLOGY FOOTPRINT
11.5.5.4 Application footprint
TABLE 390 GENOTYPING ASSAY MARKET: APPLICATION FOOTPRINT
11.5.5.5 Region footprint
TABLE 391 GENOTYPING ASSAY MARKET: REGION FOOTPRINT
11.6 COMPETITIVE EVALUATION MATRIX: STARTUPS/SMES, 2023
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
FIGURE 46 GENOTYPING ASSAY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
TABLE 392 GENOTYPING ASSAY MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 393 GENOTYPING ASSAY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
11.7 VALUATION & FINANCIAL METRICS
FIGURE 47 EV/EBITDA OF KEY VENDORS
FIGURE 48 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
11.8 BRAND/PRODUCT COMPARISON
FIGURE 49 GENOTYPING ASSAY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
11.8.1 THERMO FISHER SCIENTIFIC INC.
11.8.2 AGILENT TECHNOLOGIES, INC.
11.8.3 QIAGEN
11.8.4 ILLUMINA, INC.
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES, DEVELOPMENTS, AND APPROVALS
TABLE 394 GENOTYPING ASSAY MARKET: PRODUCT LAUNCHES, DEVELOPMENTS, AND APPROVALS, JANUARY 2020–MARCH 2024
11.9.2 DEALS
TABLE 395 GENOTYPING ASSAY MARKET: DEALS, JANUARY 2020–MARCH 2024
12 COMPANY PROFILES
12.1 KEY PLAYERS
(Business overview, Products/Services/Solutions offered, Recent developments, MnM view, Key strengths, Strategic choices, and Weaknesses and Competitive threats)*
12.1.1 THERMO FISHER SCIENTIFIC INC.
TABLE 396 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
FIGURE 50 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
TABLE 397 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 398 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2020–MARCH 2024
TABLE 399 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2020–MARCH 2024
12.1.2 ILLUMINA, INC.
TABLE 400 ILLUMINA, INC.: COMPANY OVERVIEW
FIGURE 51 ILLUMINA, INC.: COMPANY SNAPSHOT (2023)
TABLE 401 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 402 ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2020–MARCH 2024
TABLE 403 ILLUMINA, INC.: DEALS, JANUARY 2020–MARCH 2024
TABLE 404 ILLUMINA, INC.: EXPANSIONS, JANUARY 2020–MARCH 2024
12.1.3 DANAHER CORPORATION
TABLE 405 DANAHER CORPORATION: COMPANY OVERVIEW
FIGURE 52 DANAHER CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 406 DANAHER CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 407 DANAHER CORPORATION: PRODUCT LAUNCHES, JANUARY 2020–MARCH 2024
TABLE 408 DANAHER CORPORATION: DEALS, JANUARY 2020–MARCH 2024
12.1.4 QIAGEN
TABLE 409 QIAGEN: COMPANY OVERVIEW
FIGURE 53 QIAGEN: COMPANY SNAPSHOT (2023)
TABLE 410 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 411 QIAGEN: PRODUCT LAUNCHES AND DEVELOPMENTS, JANUARY 2020–MARCH 2024
TABLE 412 QIAGEN: DEALS, JANUARY 2020–MARCH 2024
12.1.5 EUROFINS SCIENTIFIC
TABLE 413 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
FIGURE 54 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2023)
TABLE 414 EUROFINS SCIENTIFIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 415 EUROFINS SCIENTIFIC: PRODUCT AND SERVICE LAUNCHES, JANUARY 2020–MARCH 2024
TABLE 416 EUROFINS SCIENTIFIC: DEALS, JANUARY 2020–MARCH 2024
12.1.6 F. HOFFMANN-LA ROCHE LTD.
TABLE 417 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
FIGURE 55 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
TABLE 418 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 419 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES, JANUARY 2020–MARCH 2024
TABLE 420 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2020–MARCH 2024
12.1.7 AGILENT TECHNOLOGIES, INC.
TABLE 421 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
FIGURE 56 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
TABLE 422 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 423 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2020–MARCH 2024
12.1.8 BIO-RAD LABORATORIES, INC.
TABLE 424 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
FIGURE 57 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)
TABLE 425 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.1.9 MERCK KGAA
TABLE 426 MERCK KGAA: COMPANY OVERVIEW
FIGURE 58 MERCK KGAA: COMPANY SNAPSHOT (2023)
TABLE 427 MERCK KGAA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.1.10 STANDARD BIOTOOLS
TABLE 428 STANDARD BIOTOOLS: COMPANY OVERVIEW
FIGURE 59 STANDARD BIOTOOLS: COMPANY SNAPSHOT (2023)
TABLE 429 STANDARD BIOTOOLS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.2 OTHER PLAYERS
12.2.1 REVVITY
TABLE 430 REVVITY: COMPANY OVERVIEW
12.2.2 PACBIO
TABLE 431 PACBIO: COMPANY OVERVIEW
12.2.3 LUMINEX CORPORATION (A DIASORIN COMPANY)
TABLE 432 LUMINEX CORPORATION (A DIASORIN COMPANY): COMPANY OVERVIEW
12.2.4 OXFORD NANOPORE TECHNOLOGIES PLC
TABLE 433 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY OVERVIEW
12.2.5 GENEWIZ, INC.
TABLE 434 GENEWIZ, INC.: COMPANY OVERVIEW
12.2.6 TAKARA BIO INC.
TABLE 435 TAKARA BIO INC.: COMPANY OVERVIEW
12.2.7 BGI GROUP
TABLE 436 BGI GROUP: COMPANY OVERVIEW
12.2.8 PROMEGA CORPORATION
TABLE 437 PROMEGA CORPORATION: COMPANY OVERVIEW
12.2.9 NOVOGENE CO., LTD.
TABLE 438 NOVOGENE CO., LTD.: COMPANY OVERVIEW
12.2.10 GENSCRIPT
TABLE 439 GENSCRIPT: COMPANY OVERVIEW
12.2.11 NEW ENGLAND BIOLABS
TABLE 440 NEW ENGLAND BIOLABS: COMPANY OVERVIEW
12.2.12 PARAGON GENOMICS, INC.
TABLE 441 PARAGON GENOMICS, INC.: COMPANY OVERVIEW
12.2.13 NEOGENOMICS LABORATORIES
TABLE 442 NEOGENOMICS LABORATORIES: COMPANY OVERVIEW
12.2.14 TECAN TRADING AG
TABLE 443 TECAN TRADING AG: COMPANY OVERVIEW
12.2.15 GENOTYPIC TECHNOLOGY PVT. LTD.
TABLE 444 GENOTYPIC TECHNOLOGY PVT. LTD.: COMPANY OVERVIEW
*Details on Business overview, Products/Services/Solutions offered, Recent developments, MnM view, Key strengths, Strategic choices, and Weaknesses and Competitive threats might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
The global genotyping market is expected to reach $17.0 Billion in 2020 from $ 6.2 Billion in 2015, at a healthy CAGR of 22.3% from 2015 to 2020.
Growth in this market is attributed to the increasing incidence of genetic diseases & increasing awareness about personalized medicine, technological advancements, decreasing prices of DNA sequencing, growing importance of SNP genotyping in drug development, and the increasing demand for genetic analysis in animal & plant livestock. However, the lack of appropriate reimbursement policies and a lack of technical know-how are curbing market growth to a certain extent.
Key players in Genotyping Market are
- Affymetrix, Inc. (U.S.)
- Illumina, Inc. (U.S.)
- Thermo Fisher Scientific, Inc. (U.S.)
- Agilent Technologies (U.S.)
- Beckman Coulter (U.S.)
- Sequenom, Inc. (U.S.)
The global genotyping market is segmented by products & services, technology, applications, end users, and region. This report also discusses the key market drivers, restraints, opportunities, and challenges for this market and submarkets. The market, by products & services, is segmented into instruments (sequencers & amplifiers, and analyzers), reagents & kits, bioinformatics software and genotyping services. The reagents & kits market segment accounted for the largest share of 49% of the global genotyping market in 2014. The accessibility of a wide range of reagents and increasing need for genotyping for assessing drug efficacy and safety, to personalize the treatment for chronic diseases, to develop good breeds of animals & plants are some of the factors that are expected to drive the genotyping reagents market.
North America, a major market for global genotyping, occupied a major share in this market, closely followed by Europe. However, emerging countries in the Asia-Pacific region and the Rest of the World (Latin America) are expected to record strong growth during the forecast period. The Asia-Pacific market is expected to grow at a CAGR of 25.4% during the forecast period of 2015-2020. Countries like India, China, and Brazil will majorly drive market growth owing to the introduction of healthcare reforms, rising investments by public and private players to provide improved healthcare services in these countries, and the unmet medical needs of patients suffering from diseases such as cancer, diabetes and cardiovascular disease.
